Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease

Tingxiang Yan, Jingjing Liang, Ju Gao, Luwen Wang, Hisashi Fujioka, Michael W. Weiner, Norbert Schuff, Howard J. Rosen, Bruce L. Miller, David C. Perry, Paul Aisen, Arthur W. Toga, Gustavo Jiménez, Michael Donohue, Devon Gessert, Kelly Harless, Jennifer Salazar, Yuliana Cabrera, Sarah Walter, Lindsey Hergesheimer, Karen Crawford, Scott Neu, Lon S. Schneider, Sonia Pawluczyk, Mauricio Becerra, Liberty Teodoro, Bryan M. Spann, Ronald Petersen, Clifford R. Jack, Matt A. Bernstein, Bret Borowski, Jeff Gunter, Matthew L. Senjem, Prashanthi Vemuri, David T. Jones, Kejal Kantarci, Chad Ward, Sara S. Mason, Colleen S. Albers, David S. Knopman, Kris Johnson, Neill R. Graff‐Radford, Francine Parfitt, Kim Poki-Walker, William J. Jagust, Susan Landau, John Q. Trojanowki, Leslie M. Shaw, Jason Karlawish, David A. Wolk, Sanjeev Vaishnavi, Christopher Clark, Steven E. Arnold, Virginia M.‐y. Lee, Magdalena Korecka, Michal Figurski, Laurel Beckett, Danielle Harvey, Charles DeCarli, Evan Fletcher, Pauline Maillard, John Olichney, Owen Carmichael, Robert C. Green, Reisa A. Sperling, Keith A. Johnson, Gad A. Marshall, Andrew J. Saykin, Tatiana Foroud, Li Shen, Kelley Faber, Sungeun Kim, Kwangsik Nho, Martin R. Farlow, Ann Marie Hake, Brandy R. Matthews, Jared R. Brosch, Scott Herring, John C. Morris, Marc Raichle, David M. Holtzman, Nigel J. Cairns, Erin Franklin, Lisa Taylor‐Reinwald, Beau M. Ances, David Winkfield, Maria Carroll, Angela Oliver, Mary L. Creech, Mark A. Mintun, Stacy Schneider, Lew Kuller, Chester A. Mathis, Oscar L. López, MaryAnn Oakley, Donna M. Simpson, Steven M. PaulNature Communications 2022 · DOI · OpenAlex

This article provides a formal correction to the 2020 study "FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease," published in Nature Communications. The original research identified FAM222A, a protein the authors named "Aggregatin," as a key factor in the development of Alzheimer’s disease pathology. This update rectifies a data presentation error in the visual evidence supporting the protein's role in amyloid-beta (Aβ) aggregation.

The Role of Aggregatin in Alzheimer’s Disease

Alzheimer’s disease is characterized by the accumulation of amyloid-beta (Aβ1–42) plaques in the brain. The original study investigated how FAM222A interacts with Aβ1–42 to facilitate this process. The researchers found that Aggregatin acts as a scaffold or catalyst, promoting the formation of dense, complex amyloid deposits.

Correcting the Experimental Record

The primary focus of this correction is Figure 4g, which displays Transmission Electron Microscopy (TEM) images of protein aggregation over time. In the original publication, the image for the "6-hour" time point in the experimental group (Aβ1–42 + rAggregatin) was a duplicate of the "0.5-hour" control group (Aβ1–42 alone).

The corrected Figure 4g now provides the unique, intended image for the 6-hour experimental condition, ensuring the visual data accurately reflects the kinetics of protein assembly.

Transmission electron microscopy (TEM) images showing the time-course of Aβ1–42 aggregation with and without rAggregatin. The corrected 6h image in the bottom row shows the distinct morphology of early protein clusters.

Visualizing Aggregation Kinetics

The researchers utilized TEM to observe the physical transition of Aβ1–42 from small monomers and oligomers into elongated, needle-like fibrils. The study compared two conditions:

  1. Control: Aβ1–42 alone.
  2. Experimental: Aβ1–42 combined with recombinant Aggregatin (rAggregatin).

Samples were imaged at four critical intervals: 0.5 hours, 6 hours, 2 weeks, and 4 weeks. The 6-hour mark is particularly significant in protein folding studies, as it often represents the transition phase where protofibrils begin to stabilize.

Key Insights from the Corrected Data

The corrected 6-hour image for the "Aβ1–42 + rAggregatin" group reveals a distinct morphology of protein clusters that differs significantly from the 0.5-hour baseline. Over the subsequent weeks, these clusters evolve into the complex fibrillar structures characteristic of Alzheimer's plaques.

By comparing the top row (Aβ alone) to the bottom row (Aβ + Aggregatin) in Figure 4g, the accelerating effect of FAM222A becomes visually apparent. The presence of Aggregatin results in denser and more structurally complex aggregates over time, supporting the conclusion that this protein plays a pivotal role in plaque accumulation.

Conclusion

While the error in the original manuscript was a matter of visual duplication, this correction is vital for maintaining the integrity and verifiability of the study's findings. The corrected Figure 4g reinforces the morphological evidence that FAM222A (Aggregatin) is a potent promoter of amyloid-beta aggregation, a discovery that remains central to our understanding of Alzheimer's disease progression.

Summary updated

Abstract

Correction to: Nature Communications 10.1038/s41467-019-13962-0, published online 21 January 2020. In the original version of the manuscript, the image shown in Figure 4g, bottom row (Aβ1–42 + rAggregatin), under “6h” was incorrect. This image incorrectly showed the same sample as shown in the original Figure 4g, top row (Aβ1–42), under “0.5h”.
BibTeX
@inproceedings{yan2022author,
  author = {Tingxiang Yan and Jingjing Liang and Ju Gao and Luwen Wang and Hisashi Fujioka and Michael W. Weiner and Norbert Schuff and Howard J. Rosen and Bruce L. Miller and David C. Perry and Paul Aisen and Arthur W. Toga and Gustavo Jiménez and Michael Donohue and Devon Gessert and Kelly Harless and Jennifer Salazar and Yuliana Cabrera and Sarah Walter and Lindsey Hergesheimer and Arthur W. Toga and Karen Crawford and Scott Neu and Lon S. Schneider and Sonia Pawluczyk and Mauricio Becerra and Liberty Teodoro and Bryan M. Spann and Paul Aisen and Ronald Petersen and Clifford R. Jack and Matt A. Bernstein and Bret Borowski and Jeff Gunter and Matthew L. Senjem and Prashanthi Vemuri and David T. Jones and Kejal Kantarci and Chad Ward and Sara S. Mason and Colleen S. Albers and David S. Knopman and Kris Johnson and Neill R. Graff‐Radford and Francine Parfitt and Kim Poki-Walker and William J. Jagust and Susan Landau and John Q. Trojanowki and Leslie M. Shaw and Jason Karlawish and David A. Wolk and Sanjeev Vaishnavi and Christopher Clark and Steven E. Arnold and Virginia M.‐Y. Lee and Magdalena Korecka and Michal Figurski and Laurel Beckett and Danielle Harvey and Charles DeCarli and Evan Fletcher and Pauline Maillard and John Olichney and Owen Carmichael and Robert C. Green and Reisa A. Sperling and Keith A. Johnson and Gad A. Marshall and Andrew J. Saykin and Tatiana Foroud and Li Shen and Kelley Faber and Sungeun Kim and Kwangsik Nho and Martin R. Farlow and Ann Marie Hake and Brandy R. Matthews and Jared R. Brosch and Scott Herring and John C. Morris and Marc Raichle and David M. Holtzman and John C. Morris and Nigel J. Cairns and Erin Franklin and Lisa Taylor‐Reinwald and Beau M. Ances and David Winkfield and Maria Carroll and Angela Oliver and Mary L. Creech and Mark A. Mintun and Stacy Schneider and Lew Kuller and Chester A. Mathis and Oscar L. López and MaryAnn Oakley and Donna M. Simpson and Steven M. Paul},
  title = {{Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-31711-8},
}
Figure